Aeterna Zentaris Inc
F:ET8

Watchlist Manager
Aeterna Zentaris Inc Logo
Aeterna Zentaris Inc
F:ET8
Watchlist
Price: 6.56 EUR -5.75%
Market Cap: 31.9m EUR

Aeterna Zentaris Inc
Common Shares Outstanding

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Aeterna Zentaris Inc
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
Aeterna Zentaris Inc
F:ET8
Common Shares Outstanding
$3.2m
CAGR 3-Years
-13%
CAGR 5-Years
5%
CAGR 10-Years
32%
Theratechnologies Inc
TSX:TH
Common Shares Outstanding
$46m
CAGR 3-Years
-22%
CAGR 5-Years
-10%
CAGR 10-Years
-3%
Repare Therapeutics Inc
NASDAQ:RPTX
Common Shares Outstanding
$43m
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Common Shares Outstanding
$131.8m
CAGR 3-Years
-2%
CAGR 5-Years
1%
CAGR 10-Years
15%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Common Shares Outstanding
$77.1m
CAGR 3-Years
7%
CAGR 5-Years
17%
CAGR 10-Years
18%
Spectral Medical Inc
TSX:EDT
Common Shares Outstanding
CA$289.1m
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
4%
No Stocks Found

Aeterna Zentaris Inc
Glance View

Market Cap
31.9m EUR
Industry
Biotechnology

Aeterna Zentaris Inc. is a specialty biopharmaceutical company, which is engaged in commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The Company focuses on the commercialization of macimorelin in Asia and the rest of the world.

ET8 Intrinsic Value
5.72 EUR
Overvaluation 13%
Intrinsic Value
Price

See Also

What is Aeterna Zentaris Inc's Common Shares Outstanding?
Common Shares Outstanding
3.2m USD

Based on the financial report for Sep 30, 2025, Aeterna Zentaris Inc's Common Shares Outstanding amounts to 3.2m USD.

What is Aeterna Zentaris Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
32%

Over the last year, the Common Shares Outstanding growth was 2%. The average annual Common Shares Outstanding growth rates for Aeterna Zentaris Inc have been -13% over the past three years , 5% over the past five years , and 32% over the past ten years .

Back to Top